VTGN Vistagen Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1411685 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY230.4%
TTM net income YoY5.3%
TTM EPS YoY29.7%
Revenue 3-yr CAGR43.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,541.9%
Net margin-2,474.5%
FCF margin—
EBITDA margin-2,533.2%
Returns
ROE-144.9%
ROA-113.0%
ROIC (approx.)-1,250.0%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.64x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio3.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.27M | $486,000 |
| R&D expense | $54.97M | $39.38M |
| SG&A expense | $18.42M | $17.08M |
| Operating income | -$72.13M | -$55.97M |
| Pretax income | -$69.68M | -$51.41M |
| Income tax | $7,000 | $7,000 |
| Net income | -$69.69M | -$51.42M |
| EBITDA | -$71.93M | -$55.82M |
| EPS (basic) | -1.83 | -1.67 |
| EPS (diluted) | -1.83 | -1.67 |
| Weighted avg. shares (diluted) | 38.07M | 30.88M |
| Balance sheet | ||
| Cash & equivalents | $30.79M | $67.13M |
| Short-term investments | $14.61M | $13.35M |
| Current assets | $46.94M | $82.08M |
| PP&E, net | $427,000 | $476,000 |
| Total assets | $48.56M | $84.34M |
| Current liabilities | $12.79M | $12.61M |
| Total liabilities | $13.04M | $13.95M |
| Shareholders' equity | $35.52M | $70.39M |
| Cash flow statement | ||
| Operating cash flow | -$66.44M | -$42.10M |
| Investing cash flow | -$877,000 | -$13.15M |
| Financing cash flow | $30.97M | $3.21M |
| Depreciation & amortization | $199,000 | $150,000 |
| Stock-based compensation | $4.00M | $4.32M |
Free plan shows the latest 2 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.